CNS Pharmaceuticals Appoints Lynne Kelley as CMO with 20-Year Phase 1-3 Leadership
Dr. Lynne Kelley brings over 20 years of oncology and CNS drug development experience to CNS Pharmaceuticals as Chief Medical Officer, including Phase 1-3 leadership and IND, NDA and BLA approvals in major markets. Her appointment completes the executive team to advance the TPI-287 brain cancer pipeline.
1. Appointment of Lynne Kelley as Chief Medical Officer
CNS Pharmaceuticals named Dr. Lynne Kelley as Chief Medical Officer on March 2, completing its executive leadership team and enhancing its clinical and regulatory expertise for oncology and CNS drug development.
2. Extensive Oncology and Regulatory Experience
Dr. Kelley brings more than two decades of global leadership in Phase 1-3 clinical programs, having secured IND, NDA and BLA approvals and breakthrough and orphan drug designations across the United States, Europe, China and Japan while leading medical affairs at multiple biotech and medical device companies.
3. Strategic Impact on TPI-287 Pipeline
Her appointment is expected to streamline clinical development and regulatory strategy for TPI-287, the company’s lead brain cancer candidate, positioning CNS Pharmaceuticals to accelerate trial enrollment, refine regulatory pathways and enhance stakeholder value.